These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 7689661

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 5. European experience with ifosfamide in lymphomas.
    von Kalle AK, Schaadt M, Diehl V.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [Abstract] [Full Text] [Related]

  • 6. [The COP-BLAM III therapy of non-Hodgkin's lymphoma].
    Arai N, Hara A, Umeda M, Shirai T.
    Rinsho Ketsueki; 1991 Nov; 32(11):1447-52. PubMed ID: 1721937
    [Abstract] [Full Text] [Related]

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 8. [The effects of COP-BLAM regimen with G-CSF for intermediate and high grade non-Hodgkin's lymphoma].
    Niitsu N, Umeda M.
    Rinsho Ketsueki; 1995 Feb; 36(2):84-90. PubMed ID: 7536279
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
    Yamamura R, Yamane T, Aoyama Y, Nakamae H, Hasegawa T, Ohta K, Nakao Y, Ohta T, Mugitani A, Hino M.
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):373-5. PubMed ID: 15045943
    [Abstract] [Full Text] [Related]

  • 11. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W.
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [Abstract] [Full Text] [Related]

  • 12. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G, Donisi A, Casari S, Re A, Stellini R, Cadeo G, Carosi G.
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 14. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 15. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
    Zinzani PL, Martelli M, Tura S, Mandelli F.
    Haematologica; 1993 May; 78(1):40-3. PubMed ID: 7684011
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 19. [ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
    Yoshida T, Nakanishi J, Ito K, Kobayashi K, Ohtake S, Nakamura S, Matsuda T, Nakagoshi T, Natori K, Nakamura E.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):984-9. PubMed ID: 3963862
    [Abstract] [Full Text] [Related]

  • 20. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW.
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.